Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

IGC Pharma (IGC) Total Liabilities (2016 - 2025)

IGC Pharma has reported Total Liabilities over the past 15 years, most recently at $1.7 million for Q3 2025.

  • Quarterly Total Liabilities fell 44.82% to $1.7 million in Q3 2025 from the year-ago period, while the trailing twelve-month figure was $1.7 million through Sep 2025, down 44.82% year-over-year, with the annual reading at $2.4 million for FY2025, 6.35% down from the prior year.
  • Total Liabilities was $1.7 million for Q3 2025 at IGC Pharma, down from $1.9 million in the prior quarter.
  • Over five years, Total Liabilities peaked at $3.1 million in Q1 2021 and troughed at $1.7 million in Q3 2025.
  • The 5-year median for Total Liabilities is $2.4 million (2025), against an average of $2.4 million.
  • Year-over-year, Total Liabilities surged 32.75% in 2023 and then tumbled 44.82% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $1.8 million in 2021, then decreased by 3.31% to $1.8 million in 2022, then grew by 25.84% to $2.2 million in 2023, then rose by 27.79% to $2.8 million in 2024, then plummeted by 41.43% to $1.7 million in 2025.
  • Per Business Quant, the three most recent readings for IGC's Total Liabilities are $1.7 million (Q3 2025), $1.9 million (Q2 2025), and $2.4 million (Q1 2025).